Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
The MEIP news page on Stock Titan provides an organized view of public announcements and regulatory disclosures related to MEI Pharma, Inc. and its transition to Lite Strategy, Inc. These items trace the company’s path from a clinical-stage oncology business with a portfolio of cancer drug candidates to an enterprise emphasizing a Litecoin-focused digital asset treasury strategy.
Earlier news releases describe MEI Pharma’s work as a pharmaceutical company with drug candidates such as voruciclib and ME-344, along with updates on cash position, research and development spending, and the evaluation of strategic alternatives. These reports document the company’s efforts to preserve cash, consider out-licensing and merger and acquisition options, and adjust its workforce and clinical programs while seeking to maximize asset value for stockholders.
More recent articles highlight a major strategic shift: the launch of a Litecoin treasury initiative, a large private placement to fund this strategy, and the acquisition of a substantial Litecoin position. The company’s news also details the appointment of digital asset advisors, board changes linked to its treasury focus, and the formal rebranding to Lite Strategy, Inc. with a new NASDAQ ticker symbol, LITS.
Investors and researchers using this page can follow how MEI Pharma’s oncology-focused narrative evolved into a digital asset treasury story, including key milestones such as the private placement, Litecoin acquisitions, and the corporate name and ticker change. For ongoing developments after the symbol transition, users should also review news associated with Lite Strategy, Inc. under its current trading symbol.
MEI Pharma reported its Q2 fiscal results, ending December 31, 2021, highlighting significant progress in clinical trials and financial metrics. The company holds approximately $186 million in cash, allowing operations through 2023. Key developments include a 70.3% overall response rate from the Phase 2 TIDAL study for zandelisib in follicular lymphoma and FDA orphan-drug designation for the same treatment. Revenue rose to $18.2 million, and net loss was reduced to $5.8 million per share. Upcoming milestones include further clinical studies for zandelisib and other candidates.
MEI Pharma, Inc. (NASDAQ: MEIP) has announced the expansion of its management team with the appointments of Alejandro Ricart, M.D., as Senior Vice President of Clinical Development, and Yomara Gomez-Naiden as Senior Vice President of Quality. Both executives bring over 20 years of experience to the company. Dr. Ricart previously worked at TG Therapeutics and Novartis, while Ms. Gomez-Naiden has a strong background in quality assurance from AGC Biologics and Merck. The company aims to advance its cancer therapies, including zandelisib, toward regulatory approval.
MEI Pharma, Inc. (NASDAQ: MEIP) has granted inducement stock options totaling 588,000 shares to seven new employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price for these options is set at $1.93 per share, equal to the closing stock price on the grant date. Options are part of the 2021 Inducement Grant Equity Compensation Plan, with a 10-year term and a structured vesting schedule. MEI Pharma continues to focus on developing new cancer therapies, including zandelisib, which is in clinical trials for potential FDA approval.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the grant of stock options for 155,000 shares to seven new employees as an inducement to employment. The options, priced at $2.67 per share, align with the company's compensation plans and comply with Nasdaq rules. These options will vest over a 4-year period, with 25% vesting after one year and the remainder vesting monthly thereafter. MEI Pharma focuses on developing cancer therapies, currently advancing zandelisib in a Phase 2 clinical trial which may lead to FDA accelerated approval.
MEI Pharma (Nasdaq: MEIP) has successfully closed a public offering of 20,125,000 shares, raising approximately $52.3 million at $2.60 per share. The offering included 2,625,000 shares from underwriters' exercised options. Proceeds are earmarked for advancing clinical programs and supporting the launch of zandelisib, pending FDA approval, along with general corporate needs. Jefferies, Stifel, and Wells Fargo Securities served as joint book-running managers.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the grant of stock options totaling 166,000 shares to six new employees as an inducement for their employment. The stock options were issued at an exercise price of $3.37 per share, matching the closing stock price on the grant date. These options are part of the 2021 Inducement Grant Equity Compensation Plan and have a 10-year term. Vesting occurs with 25% on the first anniversary and the remainder monthly thereafter. MEI Pharma focuses on developing cancer therapies, including zandelisib, which is in clinical trials.
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a priced public offering of 17,500,000 shares of its common stock at $2.60 per share, aiming for total gross proceeds of $45,500,000. The offering, set to close on December 6, 2021, includes a 30-day option for underwriters to purchase an additional 2,625,000 shares. Proceeds will support clinical development programs, the launch of zandelisib pending FDA approval, and other corporate purposes. Jefferies, Stifel, and Wells Fargo Securities are the joint book-running managers for the offering.
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a public offering of 17,500,000 shares of its common stock. The underwriters have a 30-day option to purchase an additional 15% of the shares. Proceeds will support clinical development programs and the potential commercial launch of zandelisib, pending FDA approval. The offering is subject to market conditions, and the actual size and terms may vary. Jefferies, Stifel, and Wells Fargo Securities are managing the offering.
MEI Pharma announced promising results from the pivotal Phase 2 TIDAL study of zandelisib in patients with relapsed/refractory follicular lymphoma. The study showed a 70.3% objective response rate and a 35.2% complete response rate among 91 patients. The drug was generally well tolerated, with a 9.9% discontinuation rate due to drug-related adverse events. The study is part of ongoing efforts to seek FDA approval for zandelisib, which has already received Fast Track and Orphan Drug designations.
MEI Pharma, Inc. (NASDAQ: MEIP) announced a live investor and analyst webcast scheduled for November 30, 2021. The event will discuss data from the ongoing Phase 2 TIDAL study of zandelisib, a potential treatment for relapsed or refractory follicular lymphoma. The webcast will also cover updates on the zandelisib program. Investors can access the live audio webcast through MEI's website, with a replay available for 30 days post-event. MEI Pharma focuses on developing innovative cancer therapies and has multiple clinical-stage assets.